Abstract
High serum levels of soluble TRAIL (sTRAIL) before or during the first year of Interferon-beta (IFN-beta) therapy were shown to predict an individual therapeutic response of patients with relapsing-remitting multiple sclerosis (RRMS). Here, we investigated whether sTRAIL plasma levels during long-term IFN-beta treatment correlate with future therapeutic response or adverse effects of treatment. Postinjection short-time bursts of sTRAIL were associated with flu-like symptoms and IP-10/CXCL10 as well as MCP-1/CCL2 induction, and were detected after up to 6 years of continuous IFN-beta therapy. However, neither sTRAIL nor chemokine levels allowed prediction of one- and two-year clinical treatment response in 30 RRMS patients, prospectively followed by blinded investigators.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Biomarkers / blood
-
Chemokine CCL2 / blood*
-
Chemokine CCL2 / drug effects
-
Chemokine CCL2 / immunology
-
Chemokine CXCL10 / blood*
-
Chemokine CXCL10 / drug effects
-
Chemokine CXCL10 / immunology
-
Female
-
Humans
-
Influenza, Human / chemically induced
-
Influenza, Human / immunology
-
Influenza, Human / physiopathology
-
Interferon-beta / adverse effects*
-
Interferon-beta / immunology*
-
Male
-
Middle Aged
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
-
Predictive Value of Tests
-
Prospective Studies
-
TNF-Related Apoptosis-Inducing Ligand / blood*
-
TNF-Related Apoptosis-Inducing Ligand / drug effects
-
TNF-Related Apoptosis-Inducing Ligand / immunology
Substances
-
Biomarkers
-
CCL2 protein, human
-
CXCL10 protein, human
-
Chemokine CCL2
-
Chemokine CXCL10
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFSF10 protein, human
-
Interferon-beta